Alnylam Pharma (ALNY) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $162.49 +1.63%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.32), $0.02 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $10.95 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $199 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
